Figure 5
In-silico analysis of the correlation between SMARCB1 gene expression and clinicopathological characteristics of osteosarcoma patients using data obtained from the TARGET-OS project
High SMARCB1 gene expression was observed in samples with no metastasis (A) and with good response to neoadjuvant chemotherapy (B). In survival analysis, patients with high SMARCB1 gene expression tended to show better OS (C) and PFS (D) compared with patients with low SMARCB1 gene expression.